Farnesyl transferase inhibitors: A novel targeted therapy for cancer

Lancet Oncology

Volumn 2, Issue 1, 2001, Pages 18-26

  Johnston, Stephen R D ^a  

^a Fulham Road SW3 6JJ   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESYL TRANS TRANSFERASE; TRANSFERASE;

DRUG ANTAGONISM; FORECASTING; GENETICS; HUMAN; NEOPLASM; ONCOGENE RAS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN PROCESSING; REVIEW;

ALKYL AND ARYL TRANSFERASES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; FARNESYLTRANSTRANSFERASE; FORECASTING; GENES, RAS; HUMANS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 0035240617     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00191-1     Document Type: Review

References (78)

1. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
2. Barbacid M. ras genes. Ann Rev Biochem. 62:1987;779-827.
3. McCormack F. Activators and effectors of ras p21 proteins. Curr Opin Genet Dev. 4:1994;71-76.
4. Leevers S.J., Paterson H.F., Marshall C.J. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature. 369:1994;411-414.
5. Marshall C.J. Cell signalling. Raf gets it together. Nature. 383:1996;127-128.
6. Lange-Carter C.A., Pleiman C.M., Gardner A.M., et al. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science. 260:1993;315-319.
7. Ridley A.J., Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibres in response to growth factors. Cell. 70:1992;389-399.
8. Kodaki T., Woscholski R., Hallberg B., et al. The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol. 4:1994;798-806.
9. Kennedy S.G., Wagner A.J., Conzen S.D., et al. The PI3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 11:1997;701-713.
10. McCormick F. Ras biology in atomic detail. Nat Struct Biol. 3:1996;653-655.
11. Shih C., Weinberg R.A. Isolation of transforming sequence from a human bladder cancer cell line. Cell. 29:1982;161-169.
12. Lowry D.R., Willumsen B.M. Function and regulation of Ras. Ann Rev Biochem. 62:1993;851-891.
13. Meredith J.E., Fazeli B., Schwartz M.A. The extracellular matrix as a cell survival pathway. Mol Biol Cell. 4:1993;953-961.
14. Frisch S.M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 124:1994;619-626.
15. Rak J., Mitsuhashi Y., Erdos V., et al. Massive programmed cell death in intestinal cells induced by three-dimensional growth conditions: suppression by mutant c-Ha-ras oncogene expression. J Cell Biol. 131:1995;1587-1598.
16. Rak J., Mitsuhashi Y., Bayko L., et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55:1995;4575-4580.
17. Clark G.J., Der C.J. ras proto-oncogene activation in human malignancy. Markers C.T., Garret T., Sell S. Cellular cancer. 1995;17-52 Humana Press, Totowa, NJ.
18. Clark G.J., Der C.J. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat. 35:1995;133-144.
19. Norgaard P., Law B., Joseph H., et al. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res. 5:1999;35-42.
20. Clark G.J., Kinch M.S., Gilmer T.M., Burridge K., Der C.J. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene. 12:1996;169-176.
21. Guha A., Feldkamp M.M., Lau N., Bos G., Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene. 15:1997;2755-2765.
22. Kato K., Cox A.D., Hisaka M.M., et al. Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA. 89:1992;6403-6407.
23. Moores S.L., Schaber M.D., Mosser S.D., et al. Sequence dependence of protein isoprenylation. J Biol Chem. 166:1991;14603-14610.
24. Gibbs J.B. Lipid modifications or proteins in the Ras superfamily. Birnbaumer L., Dickey B. GTPases in biology. 1993;335-344 Springer-Verlag, New York.
25. Casey P.J., Seabra M.C. Protein prenyltransferases. J Biol Chem. 271:1996;5289-5292.
26. James G.L., Goldstein J.L., Brown M.S. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetics in vitro. J Biol Chem. 266:1995;14603-14610.
27. Armstrong S.A., Hannah V.C., Goldstein J.L., et al. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB. J Biol Chem. 270:1995;7864-7868.
28. Leonard D.M. Ras farnesyltransferase: a new therapeutic target. J Med Chem. 40:1997;2971-2990.
29. Rowinsky E.K., Windle J.J., VonHoff D.D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 17:1999;3631-3652.
30. Reiss Y., Goldstein J.L., Seabra M.C., et al. Inhibition of purified p21Ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell. 62:1990;81-88.
31. Sepp-Lorenzino L., Ma Z., Rands E., et al. A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55:1995;5302-5309.
32. Khol N.E., Omer C.A., Conner M.W., et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med. 1:1995;792-797.
33. Qian Y., Blaskovich M.A., Saleem M., et al. Design and structural requirements of potent peptidomimetics inhibitors of p21ras farnesyltransferase. J Biol Chem. 269:1994;12410-12413.
34. Manne V., Yan N., Carboni J.M., et al. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene. 10:1995;1763-1779.
35. Bishop W.R., Bond R., Petrin J., et al. Novel tricyclic inhibitors of farnesyl protein transferase. J Biol Chem. 270:1995;30611-30618.
36. Liu M., Bryant M.S., Chen J., et al. Anti-tumour activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumour xenograft models and wap-ras transgenic mice. Cancer Res. 58:1998;4947-4956.
37. Skrzat S., Angibaud P., Venet M., et al. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI) with potent oral antitumour activity. Proc Am Assoc Cancer Res. 39:1998;317. abstr 2169.
38. Todd A.V., Applegate T.L., Fuery C.J., et al. Farnesyl transferase inhibitor (FTI): effect of ras activation. Proc Am Assoc Cancer Res. 39:1998;317. abstr 2168.
39. Smets G., Xhonneux B., Cornelissen F., et al. R115777, a selective farnesyl protein transferase inhibitor (FTI) induces anti-angiogenic, apoptotic and anti-proliferative activity in CAPAN-2 and LoVo tumour xenografts. Proc Am Assoc Cancer Res. 39:1998;318. abstr 2170.
40. Fiordalisi J.J., Rushton B.C., Toussaint L.G., Johnson R.L., Cox A.D. High affinity for FTPase and alternative prenylation contribute individually to K-Ras resistance to FTIs. Proc Am Assoc Cancer Res. 40:1999;521.
41. James G., Goldstein J.L., Brown M.S. Resistance of K-RasB proteins to farnesyltransferase inhibitors in Rat1 cells. Proc Natl Acad Sci USA. 93:1996;4454-4458.
42. Prendergast G.C., Davide J.P., deSolms S.J., et al. Farnesylytransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of actin cytoskeleton. Mol Cell Biol. 14:1994;4193-4202.
43. Lerner E.C., Qian Y., Blaskovich M.A., et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras/Raf complexes. J Biol Chem. 270:1995;26802-26806.
44. Cox A.D., Der C.J. Farnesyltransferase inhibitors and cancer treatment: targeting simply ras? Biochim Biophys Acta. 1333:1997;F51-71.
45. Miquel K., Pradines A., Sun J., et al. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res. 57:1997;1846-1850.
46. Sepp-Lorenzino L., Rosen N. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild-type tumor cells. J Biol Chem. 273:1998;20243-20251.
47. Du W., Lebowitz P.F., Prendergast G.C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol. 19:1999;1831-1840.
48. Lebowitz P.F., Sakamuro D., Prendergast G.C. Farnesylytransferase inhibitors induce apoptosis of ras-transformed cells denied substratum attachment. Cancer Res. 57:1997;708-713.
49. Suzuki N., Urano J., Tamanoi F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci USA. 95:1998;15356-15361.
50. Feldkamp M.M., Lau N., Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene. 18:1999;7514-7526.
51. Du W., Liu A., Prendergast G.C. Activation of the PI3'K-AKT pathway masks the pro-apoptotic effects of farnesyltransferase inhibitors. Cancer Res. 59:1999;4208-4212.
52. Moasser M.M., Sepp-Lorenzino L., Khol N.E., et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA. 95:1998;1369-1374.
53. Ranganathan S., McCauley R.A., Hudes G.R. Combined cell cycle and cytotoxic effects of paclitaxel and R115777, a specific inhibitor of p21 ras function and protein farnesylation in human prostate and breast carcinoma cell lines. Proc Am Assoc Cancer Res. 40:1999;A3448. abstr.
54. Skrazt S.G., Bowden C.R., End D.W. Interaction of the farnesyl protein transferase inhibitor R115777 with cytotoxic chemotherapeutics in vitro and in vivo. Proc Am Assoc Cancer Res. 40:1999;A3447. abstr.
55. Shi B., Gurnani M., Yaremko B., et al. Enhanced efficacy of the farnesyl protein transferase inhibitor SCH66336 in combination with paclitaxel. Proc Am Assoc Cancer Res. 40:1999;A3457. abstr.
56. Ashar H.R., James L., Gray K., et al. The farnesyl transferase inhibitor SCH66336 induces cell cycle changes in sensitive human tumor cell lines and prevents the farnesylation of the centromere associated proteins CENP-E and CENP-F. Proc Am Assoc Cancer Res. 41:2000;A1398. abstr.
57. Britten C.D., Rowinsky E., Yao S.-L., et al. The farnesyl protein transferase (FTPase) inhibitor L-788,123 in patients with solid cancers. Proc Am Soc Clin Oncol. 18:1999;A597. abstr.
58. Rubin E., Abbruzzese L.J., Morrison B.W., et al. Phase I trial of the farnesyl protein transferase (FPTase) inhibitor L-778,123 on a 14 or 28-day dosing schedule. Proc Am Soc Clin Oncol. 19:2000;A689. abstr.
59. Ryan D.P., Eder J.P., Supko J.G., et al. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 in patients with advanced solid tumors. Proc Am Soc Clin Oncol. 19:2000;A720. abstr.
60. Sonnichsen D., Damle B., Manning J., et al. Pharmacokinetics and pharmacodynamics of the farnesyltransferase inhibitor BMS-214662 in patients with advanced solid tumors. Proc Am Soc Clin Oncol. 19:2000;A691. abstr.
61. Adjei A.A., Erlichman C., Davis J.D., et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 60:2000;1871-1877.
62. Hurwitz H.I., Colvin O.M., Petros W.P., et al. Phase I and pharmacokinetic study of SCH66336, a novel FPTI using a 2-week on, 2-week off schedule. Proc Am Soc Clin Oncol. 18:1999;A599. abstr.
63. Eskens F., Awada A., Verweij J., et al. Phase I and pharmacologic study of continuous daily oral SCH66336, a novel farnesyl transferase inhibitor in patients with solid tumors. Proc Am Soc Clin Oncol. 18:1999;A600. abstr.
64. Zujewski J., Horak I.D., Bol C.J., et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 18:2000;927-935.
65. Hudes G.R., Schol J., Baab J., et al. Phase I clinical and pharmacokinetic trial of the farnesylytransferase inhibitor R115777 on a 21-day dosing schedule. Proc Am Soc Clin Oncol. 18:1999;A601. abstr.
66. Schellens J.H., deKlerk G., Swart M., et al. Phase I and pharmacokinetic study with the novel farnesyltransferase inhibitor R115777. Proc Am Soc Clin Oncol. 19:2000;A715. abstr.
67. Sharma S., Britten C., Spriggs D., et al. A phase I and PK study of farnesyl transferase inhibitor L-788,123 adminstered as a seven day continuous infusion in combination with paclitaxel. Proc Am Soc Clin Oncol. 19:2000;A719. abstr.
68. Khuri F.R., Glisson B.S., Meyers M.L., et al. Phase I study of farnesyltransferase inhibitor SCH66336 with paclitaxel in solid tumours: dose-finding, pharmacokinetics, efficacy/safety. Proc Am Soc Clin Oncol. 19:2000;A799. abstr.
69. Patnik A., Eckhardht S., Itzbicka E., et al. A phase I pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with gemcitabine. Proc Am Soc Clin Oncol. 19:2000;A5A.
70. Hurwitz H.I., Amado R., Prager D., et al. Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers. Proc Am Soc Clin Oncol. 19:2000;A717. abstr.
71. Peeters M., VanCustem E., Marse H., et al. Phase I combination trial of the farnesyltransferase inhibitor R115777 with a 5FU/LV regimen in advanced colorectal or pancreatic cancer. Proc Am Soc Clin Oncol. 18:1999;A859. abstr.
72. Bernhard E.J., Kao G., Cox A.D., et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras transformed rat embryo fibroblasts. Cancer Res. 56:1996;1727-1730.
73. Bernhard E.J., McKenna W.G., Hamilton A.D., et al. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res. 58:1998;1754-1761.
74. Muschal R.J., Soto D.E., McKenna W.G., Bernhard E.J. Radiosensitization and apoptosis. Oncogene. 17:1998;3359-3363.
75. Hahn S.M., Kiel K., Morrison B.W., et al. Phase I trial of farnesyl protein transferase inhibitor L-778,123 in combination with radiotherapy. Proc Am Soc Clin Oncol. 19:2000;A906. abstr.
76. Lancet J., Rosenblatt J.L., Liesveld J.L., et al. Use of farnesyl transferase inhibitor R115777 in relapsed and refractory acute leukemias: preliminary results of a phase I trial. Proc Am Soc Clin Oncol. 19:2000;A5B. abstr.
77. Johnston S.R.D., Ellis P.A., Houston S., et al. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer. Proc Am Soc Clin Oncol. 19:2000;A318. abstr.
78. Adeji A.A., Davis J.N., Erlichman C., Svingen P.A., Kaufmann S.H. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res. 6:2000;2318-2325.